Shopping Cart 0
Cart Subtotal
AED 0

Global Omega 3 Ingredients for Pharmaceuticals Market - Industry Trends and Forecast to 2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 17616

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 25690

Details

Global omega-3 ingredients for pharmaceuticals market is projected to register a healthy CAGR of 11.0% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA), Alpha-Linolenic Acid (ALA)), Forms (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer, Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa)-Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of global omega-3 ingredients for pharmaceuticals market are:

Growing demand of functional and supplement food

Rising burden of lifestyle diseases leads the demand of omega-3 based products

Market Players:

The key market players for global omega-3 ingredients for pharmaceuticals market are listed below:

Avestia Pharma

Novasep

AbbVie Inc.

KD Pharma Group

BASF SE

Corbion NV

DSM

AstraZeneca

GlaxoSmithKline plc.

Fresenius Kabi AG

Croda International Plc

AMARIN CORPORATION

ANI Pharmaceuticals, Inc.

Epax

Strides Pharma Science Limited

Pharma Marine AS

KinOmega Biopharm Inc.

Camber Pharmaceuticals, Inc.

Solutex

BASF SE

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1 INTRODUCTION 47

1.1 OBJECTIVES OF THE STUDY 47

1.2 MARKET DEFINITION 47

1.3 OVERVIEW OF GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET 47

1.4 CURRENCY AND PRICING 49

1.5 LIMITATIONS 49

1.6 MARKETS COVERED 50

2 MARKET SEGMENTATION 54

2.1 MARKETS COVERED 54

2.2 GEOGRAPHICAL SCOPE 55

2.3 YEARS CONSIDERED FOR THE STUDY 56

2.4 DBMR TRIPOD DATA VALIDATION MODEL 57

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60

2.6 MULTIVARIATE MODELLING 61

2.7 SOURCE LIFELINE CURVE 61

2.8 DBMR MARKET POSITION GRID 62

2.9 VENDOR SHARE ANALYSIS 63

2.10 SECONDARY SOURCES 64

2.11 ASSUMPTIONS 64

3 EXECUTIVE SUMMARY 65

3.1 PATENT ANALYSIS 71

3.1.1 DBMR ANALYSIS 71

3.1.2 COUNTRY LEVEL INSIGHTS 71

3.1.3 COMPANY BASED ANALYSIS 73

3.2 PRICING ANALYSIS 74

4 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: REGULATIONS 75

5 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL OMEGA 3 INGREDIENTS IN PHARMACEUTICALS MARKET 77

5.1 PRICE IMPACT 77

5.2 IMPACT ON DEMAND 77

5.3 IMPACT ON SUPPLY CHAIN 78

5.4 STRATEGIC DECISIONS FOR MANUFACTURERS 78

5.5 CONCLUSION 79

6 MARKET OVERVIEW 80

6.1 DRIVERS 82

6.1.1 CONSUMER AWARENESS REGARDING THE HEALTH BENEFITS OF OMEGA-3 82

6.1.2 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD 83

6.1.3 INCREASING PREFERENCES TOWARDS CERTIFIED FOOD INGREDIENTS 84

6.1.4 RISING BURDEN OF LIFESTYLE DISEASES LEADS THE DEMAND OF OMEGA-3 BASED PRODUCTS 84

6.2 RESTRAINTS 86

6.2.1 NEGATIVE CONSUMER PERCEPTION ABOUT THE SMELL AND TASTE OF OMEGA-3 INGREDIENTS 86

6.2.2 HIGH COSTS OF PRODUCTS 86

6.3 OPPORTUNITIES 87

6.3.1 GROWING RESEARCH FOR THE DEVELOPMENT OF ALTERNATIVE SOURCES TO OBTAIN OMEGA-3 87

6.3.2 RISE IN CONSUMER DEMAND FOR PLANT-BASED OMEGA-3 PRODUCTS 87

6.3.3 DEVELOPING TECHNOLOGIES TO INCREASE THE CONCENTRATION OF OMEGA-3 INGREDIENTS IN MEDICINES 88

6.4 CHALLENGES 89

6.4.1 SIDE EFFECTS AND ALLERGIES RELATED TO FISH-BASED PRODUCTS 89

6.4.2 SUSTAINABILITY ISSUES WITH OMEGA-3 RAW MATERIAL 89

7 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE 90

7.1 OVERVIEW 91

7.2 MARINE 94

7.3 PLANT 95

8 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE 96

8.1 OVERVIEW 97

8.2 DOCOSAHEXAENOIC ACID (DHA) 100

8.3 EICOSAPENTAENOIC ACID (EPA) 101

8.4 ALPHA-LINOLENIC ACID (ALA) 102

9 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM 103

9.1 OVERVIEW 104

9.2 LIQUID 107

9.3 DRY 107

10 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS 109

10.1 OVERVIEW 110

10.2 CARDIOVASCULAR DISEASES 113

10.2.1 HYPERLIPIDEMIA 113

10.2.2 STROKES 114

10.2.3 HYPERTENSION 114

10.2.4 OTHERS 114

10.3 CANCER 114

10.3.1 PROSTATE CANCER 115

10.3.2 BREAST CANCER 115

10.3.3 COLORECTAL CANCER 115

10.3.4 OTHERS 115

10.4 NEUROLOGICAL DISORDERS 116

10.4.1 ALZHEIMER'S DISEASE 117

10.4.2 COGNITIVE DISORDERS 117

10.4.3 BIPOLAR DISORDERS 117

10.4.4 SCHIZOPHRENIA 117

10.4.5 OTHERS 117

10.5 AUTOIMMUNE DISEASES 118

10.5.1 RHEUMATOID ARTHRITIS 118

10.5.2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 119

10.5.3 TYPE 1 DIABETES 119

10.5.4 OTHERS 119

10.6 BONE & JOINT DISORDERS 119

10.6.1 OSTEOPOROSIS 120

10.6.2 ARTHRITIS 120

10.6.3 OTHERS 120

10.7 SKIN HEALTH 120

10.7.1 ACNE 121

10.7.2 WRINKLES 121

10.7.3 SKIN AGING 121

10.7.4 OTHERS 121

10.8 OPHTHALMIC DISORDERS 122

10.8.1 DRY EYE SYNDROME 122

10.8.2 AGE-RELATED MACULAR DEGENERATION 123

10.8.3 OTHERS 123

10.9 OTHERS 123

11 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE 124

11.1 OVERVIEW 125

11.2 ADULT 128

11.2.1 FEMALE 128

11.2.2 MALE 129

11.3 CHILDREN 129

12 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL 130

12.1 OVERVIEW 131

12.2 DIRECT 134

12.3 INDIRECT 134

13 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY GEOGRAPHY 136

13.1 OVERVIEW 137

13.2 NORTH AMERICA 142

13.2.1 U.S. 149

13.2.2 CANADA 153

13.2.3 MEXICO 157

13.3 EUROPE 161

13.3.1 GERMANY 169

13.3.2 U.K 173

13.3.3 FRANCE 177

13.3.4 NETHERLANDS 181

13.3.5 ITALY 185

13.3.6 DENMARK 189

13.3.7 SWEDEN 193

13.3.8 SPAIN 197

13.3.9 SWITZERLAND 201

13.3.10 RUSSIA 205

13.3.11 BELGIUM 209

13.3.12 TURKEY 213

13.3.13 POLAND 217

13.3.14 REST OF EUROPE 221

13.4 ASIA-PACIFIC 222

13.4.1 CHINA 230

13.4.2 JAPAN 235

13.4.3 INDIA 240

13.4.4 SOUTH KOREA 245

13.4.5 AUSTRALIA 249

13.4.6 INDONESIA 253

13.4.7 THAILAND 258

13.4.8 MALAYSIA 263

13.4.9 SINGAPORE 267

13.4.10 VIETNAM 272

13.4.11 NEW ZEALAND 277

13.4.12 PHILIPPINES 282

13.4.13 REST OF ASIA-PACIFIC 287

13.5 SOUTH AMERICA 288

13.5.1 BRAZIL 296

13.5.2 ARGENTINA 301

13.5.3 REST OF SOUTH AMERICA 306

13.6 MIDDLE EAST & AFRICA 307

13.6.1 SOUTH AFRICA 315

13.6.2 UAE 320

13.6.3 SAUDI ARABIA 325

13.6.4 KUWAIT 330

13.6.5 REST OF MIDDLE EAST AND AFRICA 335

14 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, COMPANY LANDSCAPE 336

14.1 COMPANY SHARE ANALYSIS: GLOBAL 336

14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 337

14.3 COMPANY SHARE ANALYSIS: EUROPE 338

14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 339

15 SWOT ANALYSIS 340

16 COMPANY PROFILE 341

16.1 CRODA INTERNATIONAL PLC 341

16.1.1 COMPANY SNAPSHOT 341

16.1.2 REVENUE ANALYSIS 341

16.1.3 COMPANY SHARE ANALYSIS 342

16.1.4 PRODUCT PORTFOLIO 342

16.1.5 RECENT DEVELOPMENT 342

16.2 CORBION 343

16.2.1 COMPANY SNAPSHOT 343

16.2.2 REVENUE ANALYSIS 343

16.2.3 COMPANY SHARE ANALYSIS 344

16.2.4 PRODUCT PORTFOLIO 344

16.2.5 RECENT DEVELOPMENTS 344

16.3 DSM 345

16.3.1 COMPANY SNAPSHOT 345

16.3.2 REVENUE ANALYSIS 345

16.3.3 COMPANY SHARE ANALYSIS 346

16.3.4 PRODUCT PORTFOLIO 346

16.3.5 RECENT DEVELOPMENTS 346

16.4 KD PHARMA GROUP 347

16.4.1 COMPANY SNAPSHOT 347

16.4.2 COMPANY SHARE ANALYSIS 347

16.4.3 PRODUCT PORTFOLIO 348

16.4.4 RECENT DEVELOPMENTS 349

16.5 STRIDES PHARMA SCIENCE LIMITED 350

16.5.1 COMPANY SNAPSHOT 350

16.5.2 REVENUE ANALYSIS 350

16.5.3 COMPANY SHARE ANALYSIS 351

16.5.4 PRODUCT PORTFOLIO 351

16.5.5 RECENT DEVELOPMENT 351

16.6 BASF SE 352

16.6.1 COMPANY SNAPSHOT 352

16.6.2 REVENUE ANALYSIS 352

16.6.3 PRODUCT PORTFOLIO 353

16.6.4 RECENT DEVELOPMENTS 353

16.7 PHARMA MARINE AS 354

16.7.1 COMPANY SNAPSHOT 354

16.7.2 PRODUCT PORTFOLIO 354

16.7.3 RECENT DEVELOPMENTS 354

16.8 ABBVIE INC. 355

16.8.1 COMPANY SNAPSHOT 355

16.8.2 REVENUE ANALYSIS 355

16.8.3 PRODUCT PORTFOLIO 356

16.8.4 RECENT DEVELOPMENT 356

16.9 AMARIN CORPORATION 357

16.9.1 COMPANY SNAPSHOT 357

16.9.2 REVENUE ANALYSIS 357

16.9.3 PRODUCT PORTFOLIO 358

16.9.4 RECENT DEVELOPMENTS 358

16.10 ANI PHARMACEUTICALS, INC. 359

16.10.1 COMPANY SNAPSHOT 359

16.10.2 REVENUE ANALYSIS 359

16.10.3 PRODUCT PORTFOLIO 360

16.10.4 RECENT DEVELOPMENT 360

16.11 ASTRAZENECA 361

16.11.1 COMPANY SNAPSHOT 361

16.11.2 REVENUE ANALYSIS 361

16.11.3 PRODUCT PORTFOLIO 362

16.11.4 RECENT DEVELOPMENT 362

16.12 AVESTIA PHARMA 363

16.12.1 COMPANY SNAPSHOT 363

16.12.2 PRODUCT PORTFOLIO 363

16.12.3 RECENT DEVELOPMENT 363

16.13 CAMBER PHARMACEUTICALS, INC. 364

16.13.1 COMPANY SNAPSHOT 364

16.13.2 PRODUCT PORTFOLIO 364

16.13.3 RECENT DEVELOPMENTS 364

16.14 EPAX (A SUBSIDIARY OF PELAGIA AS) 365

16.14.1 COMPANY SNAPSHOT 365

16.14.2 REVENUE ANALYSIS 365

16.14.3 PRODUCT PORTFOLIO 366

16.14.4 RECENT DEVELOPMENTS 366

16.15 FRESENIUS KABI INDIA PVT. LTD. (A SUBSIDIARY OF FRESENIUS KABI AG) 367

16.15.1 COMPANY SNAPSHOT 367

16.15.2 REVENUE ANALYSIS 367

16.15.3 PRODUCT PORTFOLIO 368

16.15.4 RECENT DEVELOPMENT 368

16.16 GLAXOSMITHKLINE PLC 369

16.16.1 COMPANY SNAPSHOT 369

16.16.2 REVENUE ANALYSIS 369

16.16.3 PRODUCT PORTFOLIO 370

16.16.4 RECENT DEVELOPMENT 370

16.17 KINOMEGA BIOPHARM INC 371

16.17.1 COMPANY SNAPSHOT 371

16.17.2 PRODUCT PORTFOLIO 371

16.17.3 RECENT DEVELOPMENTS 371

16.18 NOVASEP 372

16.18.1 COMPANY SNAPSHOT 372

16.18.2 REVENUE ANALYSIS 372

16.18.3 PRODUCT PORTFOLIO 373

16.18.4 RECENT DEVELOPMENT 373

16.19 SOLUTEX 374

16.19.1 COMPANY SNAPSHOT 374

16.19.2 PRODUCT PORTFOLIO 374

16.19.3 RECENT DEVELOPMENT 374

17 QUESTIONNAIRE 375

18 RELATED REPORTS 378


List Of Figure

LIST OF FIGURES

FIGURE 1 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION 54

FIGURE 2 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DATA TRIANGULATION 57

FIGURE 3 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DROC ANALYSIS 58

FIGURE 4 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 59

FIGURE 5 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS 59

FIGURE 6 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS 60

FIGURE 7 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID 62

FIGURE 8 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS 63

FIGURE 9 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION 67

FIGURE 10 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2020 TO 2027 68

FIGURE 11 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD IS EXPECTED TO DRIVE THE GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 69

FIGURE 12 MARINE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN 2020 & 2027 69

FIGURE 13 ASIA-PACIFIC IS THE FASTEST GROWING REGION FOR OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2020 TO 2027 70

FIGURE 14 PATENT REGISTERED FOR OMEGA-3, BY COUNTRY 71

FIGURE 15 PATENT REGISTERED BY YEAR (2000-2020) 72

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET 81

FIGURE 17 PREVALENCE OF LIFESTYLE CHRONIC DISEASES (IN MILLIONS) 85

FIGURE 18 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019 91

FIGURE 19 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019-2027 (USD THOUSANDS) 92

FIGURE 20 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, CAGR (2020-2027) 92

FIGURE 21 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE 93

FIGURE 22 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019 97

FIGURE 23 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019-2027 (USD THOUSANDS) 98

FIGURE 24 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, CAGR (2020-2027) 98

FIGURE 25 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE 99

FIGURE 26 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019 104

FIGURE 27 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019-2027 (USD THOUSANDS) 105

FIGURE 28 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, CAGR (2020-2027) 105

FIGURE 29 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, LIFELINE CURVE 106

FIGURE 30 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, 2019 110

FIGURE 31 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC ARES, 2019-2027 (USD THOUSANDS) 111

FIGURE 32 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027) 111

FIGURE 33 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE 112

FIGURE 34 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019 125

FIGURE 35 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019-2027 (USD THOUSANDS) 126

FIGURE 36 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, CAGR (2020-2027) 126

FIGURE 37 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, LIFELINE CURVE 127

FIGURE 38 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019 131

FIGURE 39 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSANDS) 132

FIGURE 40 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 132

FIGURE 41 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 133

FIGURE 42 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 138

FIGURE 43 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019) 139

FIGURE 44 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 139

FIGURE 45 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019 & 2027) 140

FIGURE 46 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE (2020-2027) 140

FIGURE 47 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 142

FIGURE 48 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019) 143

FIGURE 49 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 143

FIGURE 50 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 144

FIGURE 51 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE (2020-2027) 144

FIGURE 52 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 161

FIGURE 53 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019) 162

FIGURE 54 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 162

FIGURE 55 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 163

FIGURE 56 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE (2020-2027) 163

FIGURE 57 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 222

FIGURE 58 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019) 223

FIGURE 59 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027) 223

FIGURE 60 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027) 224

FIGURE 61 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE(2020-2027) 224

FIGURE 62 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 288

FIGURE 63 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019) 289

FIGURE 64 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027) 289

FIGURE 65 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027) 290

FIGURE 66 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE (2020-2027) 290

FIGURE 67 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 307

FIGURE 68 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019) 308

FIGURE 69 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027) 308

FIGURE 70 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027) 309

FIGURE 71 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE (2020-2027) 309

FIGURE 72 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 336

FIGURE 73 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 337

FIGURE 74 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 338

FIGURE 75 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 339

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Avestia Pharma

Novasep

AbbVie Inc.

KD Pharma Group

BASF SE

Corbion NV

DSM

AstraZeneca

GlaxoSmithKline plc.

Fresenius Kabi AG

Croda International Plc

AMARIN CORPORATION

ANI Pharmaceuticals, Inc.

Epax

Strides Pharma Science Limited

Pharma Marine AS

KinOmega Biopharm Inc.

Camber Pharmaceuticals, Inc.

Solutex

Company Profile

Company Profile Title

Global omega-3 ingredients for pharmaceuticals market is projected to register a healthy CAGR of 11.0% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA), Alpha-Linolenic Acid (ALA)), Forms (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer, Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa)-Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of global omega-3 ingredients for pharmaceuticals market are:

Growing demand of functional and supplement food

Rising burden of lifestyle diseases leads the demand of omega-3 based products

Market Players:

The key market players for global omega-3 ingredients for pharmaceuticals market are listed below:

Avestia Pharma

Novasep

AbbVie Inc.

KD Pharma Group

BASF SE

Corbion NV

DSM

AstraZeneca

GlaxoSmithKline plc.

Fresenius Kabi AG

Croda International Plc

AMARIN CORPORATION

ANI Pharmaceuticals, Inc.

Epax

Strides Pharma Science Limited

Pharma Marine AS

KinOmega Biopharm Inc.

Camber Pharmaceuticals, Inc.

Solutex

BASF SE

READ MORE

Scope

TABLE OF CONTENTS

1 INTRODUCTION 47

1.1 OBJECTIVES OF THE STUDY 47

1.2 MARKET DEFINITION 47

1.3 OVERVIEW OF GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET 47

1.4 CURRENCY AND PRICING 49

1.5 LIMITATIONS 49

1.6 MARKETS COVERED 50

2 MARKET SEGMENTATION 54

2.1 MARKETS COVERED 54

2.2 GEOGRAPHICAL SCOPE 55

2.3 YEARS CONSIDERED FOR THE STUDY 56

2.4 DBMR TRIPOD DATA VALIDATION MODEL 57

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60

2.6 MULTIVARIATE MODELLING 61

2.7 SOURCE LIFELINE CURVE 61

2.8 DBMR MARKET POSITION GRID 62

2.9 VENDOR SHARE ANALYSIS 63

2.10 SECONDARY SOURCES 64

2.11 ASSUMPTIONS 64

3 EXECUTIVE SUMMARY 65

3.1 PATENT ANALYSIS 71

3.1.1 DBMR ANALYSIS 71

3.1.2 COUNTRY LEVEL INSIGHTS 71

3.1.3 COMPANY BASED ANALYSIS 73

3.2 PRICING ANALYSIS 74

4 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: REGULATIONS 75

5 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL OMEGA 3 INGREDIENTS IN PHARMACEUTICALS MARKET 77

5.1 PRICE IMPACT 77

5.2 IMPACT ON DEMAND 77

5.3 IMPACT ON SUPPLY CHAIN 78

5.4 STRATEGIC DECISIONS FOR MANUFACTURERS 78

5.5 CONCLUSION 79

6 MARKET OVERVIEW 80

6.1 DRIVERS 82

6.1.1 CONSUMER AWARENESS REGARDING THE HEALTH BENEFITS OF OMEGA-3 82

6.1.2 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD 83

6.1.3 INCREASING PREFERENCES TOWARDS CERTIFIED FOOD INGREDIENTS 84

6.1.4 RISING BURDEN OF LIFESTYLE DISEASES LEADS THE DEMAND OF OMEGA-3 BASED PRODUCTS 84

6.2 RESTRAINTS 86

6.2.1 NEGATIVE CONSUMER PERCEPTION ABOUT THE SMELL AND TASTE OF OMEGA-3 INGREDIENTS 86

6.2.2 HIGH COSTS OF PRODUCTS 86

6.3 OPPORTUNITIES 87

6.3.1 GROWING RESEARCH FOR THE DEVELOPMENT OF ALTERNATIVE SOURCES TO OBTAIN OMEGA-3 87

6.3.2 RISE IN CONSUMER DEMAND FOR PLANT-BASED OMEGA-3 PRODUCTS 87

6.3.3 DEVELOPING TECHNOLOGIES TO INCREASE THE CONCENTRATION OF OMEGA-3 INGREDIENTS IN MEDICINES 88

6.4 CHALLENGES 89

6.4.1 SIDE EFFECTS AND ALLERGIES RELATED TO FISH-BASED PRODUCTS 89

6.4.2 SUSTAINABILITY ISSUES WITH OMEGA-3 RAW MATERIAL 89

7 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE 90

7.1 OVERVIEW 91

7.2 MARINE 94

7.3 PLANT 95

8 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE 96

8.1 OVERVIEW 97

8.2 DOCOSAHEXAENOIC ACID (DHA) 100

8.3 EICOSAPENTAENOIC ACID (EPA) 101

8.4 ALPHA-LINOLENIC ACID (ALA) 102

9 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM 103

9.1 OVERVIEW 104

9.2 LIQUID 107

9.3 DRY 107

10 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS 109

10.1 OVERVIEW 110

10.2 CARDIOVASCULAR DISEASES 113

10.2.1 HYPERLIPIDEMIA 113

10.2.2 STROKES 114

10.2.3 HYPERTENSION 114

10.2.4 OTHERS 114

10.3 CANCER 114

10.3.1 PROSTATE CANCER 115

10.3.2 BREAST CANCER 115

10.3.3 COLORECTAL CANCER 115

10.3.4 OTHERS 115

10.4 NEUROLOGICAL DISORDERS 116

10.4.1 ALZHEIMER'S DISEASE 117

10.4.2 COGNITIVE DISORDERS 117

10.4.3 BIPOLAR DISORDERS 117

10.4.4 SCHIZOPHRENIA 117

10.4.5 OTHERS 117

10.5 AUTOIMMUNE DISEASES 118

10.5.1 RHEUMATOID ARTHRITIS 118

10.5.2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 119

10.5.3 TYPE 1 DIABETES 119

10.5.4 OTHERS 119

10.6 BONE & JOINT DISORDERS 119

10.6.1 OSTEOPOROSIS 120

10.6.2 ARTHRITIS 120

10.6.3 OTHERS 120

10.7 SKIN HEALTH 120

10.7.1 ACNE 121

10.7.2 WRINKLES 121

10.7.3 SKIN AGING 121

10.7.4 OTHERS 121

10.8 OPHTHALMIC DISORDERS 122

10.8.1 DRY EYE SYNDROME 122

10.8.2 AGE-RELATED MACULAR DEGENERATION 123

10.8.3 OTHERS 123

10.9 OTHERS 123

11 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE 124

11.1 OVERVIEW 125

11.2 ADULT 128

11.2.1 FEMALE 128

11.2.2 MALE 129

11.3 CHILDREN 129

12 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL 130

12.1 OVERVIEW 131

12.2 DIRECT 134

12.3 INDIRECT 134

13 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY GEOGRAPHY 136

13.1 OVERVIEW 137

13.2 NORTH AMERICA 142

13.2.1 U.S. 149

13.2.2 CANADA 153

13.2.3 MEXICO 157

13.3 EUROPE 161

13.3.1 GERMANY 169

13.3.2 U.K 173

13.3.3 FRANCE 177

13.3.4 NETHERLANDS 181

13.3.5 ITALY 185

13.3.6 DENMARK 189

13.3.7 SWEDEN 193

13.3.8 SPAIN 197

13.3.9 SWITZERLAND 201

13.3.10 RUSSIA 205

13.3.11 BELGIUM 209

13.3.12 TURKEY 213

13.3.13 POLAND 217

13.3.14 REST OF EUROPE 221

13.4 ASIA-PACIFIC 222

13.4.1 CHINA 230

13.4.2 JAPAN 235

13.4.3 INDIA 240

13.4.4 SOUTH KOREA 245

13.4.5 AUSTRALIA 249

13.4.6 INDONESIA 253

13.4.7 THAILAND 258

13.4.8 MALAYSIA 263

13.4.9 SINGAPORE 267

13.4.10 VIETNAM 272

13.4.11 NEW ZEALAND 277

13.4.12 PHILIPPINES 282

13.4.13 REST OF ASIA-PACIFIC 287

13.5 SOUTH AMERICA 288

13.5.1 BRAZIL 296

13.5.2 ARGENTINA 301

13.5.3 REST OF SOUTH AMERICA 306

13.6 MIDDLE EAST & AFRICA 307

13.6.1 SOUTH AFRICA 315

13.6.2 UAE 320

13.6.3 SAUDI ARABIA 325

13.6.4 KUWAIT 330

13.6.5 REST OF MIDDLE EAST AND AFRICA 335

14 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, COMPANY LANDSCAPE 336

14.1 COMPANY SHARE ANALYSIS: GLOBAL 336

14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 337

14.3 COMPANY SHARE ANALYSIS: EUROPE 338

14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 339

15 SWOT ANALYSIS 340

16 COMPANY PROFILE 341

16.1 CRODA INTERNATIONAL PLC 341

16.1.1 COMPANY SNAPSHOT 341

16.1.2 REVENUE ANALYSIS 341

16.1.3 COMPANY SHARE ANALYSIS 342

16.1.4 PRODUCT PORTFOLIO 342

16.1.5 RECENT DEVELOPMENT 342

16.2 CORBION 343

16.2.1 COMPANY SNAPSHOT 343

16.2.2 REVENUE ANALYSIS 343

16.2.3 COMPANY SHARE ANALYSIS 344

16.2.4 PRODUCT PORTFOLIO 344

16.2.5 RECENT DEVELOPMENTS 344

16.3 DSM 345

16.3.1 COMPANY SNAPSHOT 345

16.3.2 REVENUE ANALYSIS 345

16.3.3 COMPANY SHARE ANALYSIS 346

16.3.4 PRODUCT PORTFOLIO 346

16.3.5 RECENT DEVELOPMENTS 346

16.4 KD PHARMA GROUP 347

16.4.1 COMPANY SNAPSHOT 347

16.4.2 COMPANY SHARE ANALYSIS 347

16.4.3 PRODUCT PORTFOLIO 348

16.4.4 RECENT DEVELOPMENTS 349

16.5 STRIDES PHARMA SCIENCE LIMITED 350

16.5.1 COMPANY SNAPSHOT 350

16.5.2 REVENUE ANALYSIS 350

16.5.3 COMPANY SHARE ANALYSIS 351

16.5.4 PRODUCT PORTFOLIO 351

16.5.5 RECENT DEVELOPMENT 351

16.6 BASF SE 352

16.6.1 COMPANY SNAPSHOT 352

16.6.2 REVENUE ANALYSIS 352

16.6.3 PRODUCT PORTFOLIO 353

16.6.4 RECENT DEVELOPMENTS 353

16.7 PHARMA MARINE AS 354

16.7.1 COMPANY SNAPSHOT 354

16.7.2 PRODUCT PORTFOLIO 354

16.7.3 RECENT DEVELOPMENTS 354

16.8 ABBVIE INC. 355

16.8.1 COMPANY SNAPSHOT 355

16.8.2 REVENUE ANALYSIS 355

16.8.3 PRODUCT PORTFOLIO 356

16.8.4 RECENT DEVELOPMENT 356

16.9 AMARIN CORPORATION 357

16.9.1 COMPANY SNAPSHOT 357

16.9.2 REVENUE ANALYSIS 357

16.9.3 PRODUCT PORTFOLIO 358

16.9.4 RECENT DEVELOPMENTS 358

16.10 ANI PHARMACEUTICALS, INC. 359

16.10.1 COMPANY SNAPSHOT 359

16.10.2 REVENUE ANALYSIS 359

16.10.3 PRODUCT PORTFOLIO 360

16.10.4 RECENT DEVELOPMENT 360

16.11 ASTRAZENECA 361

16.11.1 COMPANY SNAPSHOT 361

16.11.2 REVENUE ANALYSIS 361

16.11.3 PRODUCT PORTFOLIO 362

16.11.4 RECENT DEVELOPMENT 362

16.12 AVESTIA PHARMA 363

16.12.1 COMPANY SNAPSHOT 363

16.12.2 PRODUCT PORTFOLIO 363

16.12.3 RECENT DEVELOPMENT 363

16.13 CAMBER PHARMACEUTICALS, INC. 364

16.13.1 COMPANY SNAPSHOT 364

16.13.2 PRODUCT PORTFOLIO 364

16.13.3 RECENT DEVELOPMENTS 364

16.14 EPAX (A SUBSIDIARY OF PELAGIA AS) 365

16.14.1 COMPANY SNAPSHOT 365

16.14.2 REVENUE ANALYSIS 365

16.14.3 PRODUCT PORTFOLIO 366

16.14.4 RECENT DEVELOPMENTS 366

16.15 FRESENIUS KABI INDIA PVT. LTD. (A SUBSIDIARY OF FRESENIUS KABI AG) 367

16.15.1 COMPANY SNAPSHOT 367

16.15.2 REVENUE ANALYSIS 367

16.15.3 PRODUCT PORTFOLIO 368

16.15.4 RECENT DEVELOPMENT 368

16.16 GLAXOSMITHKLINE PLC 369

16.16.1 COMPANY SNAPSHOT 369

16.16.2 REVENUE ANALYSIS 369

16.16.3 PRODUCT PORTFOLIO 370

16.16.4 RECENT DEVELOPMENT 370

16.17 KINOMEGA BIOPHARM INC 371

16.17.1 COMPANY SNAPSHOT 371

16.17.2 PRODUCT PORTFOLIO 371

16.17.3 RECENT DEVELOPMENTS 371

16.18 NOVASEP 372

16.18.1 COMPANY SNAPSHOT 372

16.18.2 REVENUE ANALYSIS 372

16.18.3 PRODUCT PORTFOLIO 373

16.18.4 RECENT DEVELOPMENT 373

16.19 SOLUTEX 374

16.19.1 COMPANY SNAPSHOT 374

16.19.2 PRODUCT PORTFOLIO 374

16.19.3 RECENT DEVELOPMENT 374

17 QUESTIONNAIRE 375

18 RELATED REPORTS 378


List Of Figure

LIST OF FIGURES

FIGURE 1 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION 54

FIGURE 2 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DATA TRIANGULATION 57

FIGURE 3 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DROC ANALYSIS 58

FIGURE 4 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 59

FIGURE 5 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS 59

FIGURE 6 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS 60

FIGURE 7 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID 62

FIGURE 8 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS 63

FIGURE 9 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION 67

FIGURE 10 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2020 TO 2027 68

FIGURE 11 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD IS EXPECTED TO DRIVE THE GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 69

FIGURE 12 MARINE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN 2020 & 2027 69

FIGURE 13 ASIA-PACIFIC IS THE FASTEST GROWING REGION FOR OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2020 TO 2027 70

FIGURE 14 PATENT REGISTERED FOR OMEGA-3, BY COUNTRY 71

FIGURE 15 PATENT REGISTERED BY YEAR (2000-2020) 72

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET 81

FIGURE 17 PREVALENCE OF LIFESTYLE CHRONIC DISEASES (IN MILLIONS) 85

FIGURE 18 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019 91

FIGURE 19 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019-2027 (USD THOUSANDS) 92

FIGURE 20 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, CAGR (2020-2027) 92

FIGURE 21 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE 93

FIGURE 22 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019 97

FIGURE 23 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019-2027 (USD THOUSANDS) 98

FIGURE 24 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, CAGR (2020-2027) 98

FIGURE 25 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE 99

FIGURE 26 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019 104

FIGURE 27 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019-2027 (USD THOUSANDS) 105

FIGURE 28 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, CAGR (2020-2027) 105

FIGURE 29 GLOBAL TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, LIFELINE CURVE 106

FIGURE 30 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, 2019 110

FIGURE 31 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC ARES, 2019-2027 (USD THOUSANDS) 111

FIGURE 32 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027) 111

FIGURE 33 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE 112

FIGURE 34 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019 125

FIGURE 35 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019-2027 (USD THOUSANDS) 126

FIGURE 36 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, CAGR (2020-2027) 126

FIGURE 37 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, LIFELINE CURVE 127

FIGURE 38 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019 131

FIGURE 39 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSANDS) 132

FIGURE 40 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 132

FIGURE 41 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 133

FIGURE 42 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 138

FIGURE 43 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019) 139

FIGURE 44 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 139

FIGURE 45 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019 & 2027) 140

FIGURE 46 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE (2020-2027) 140

FIGURE 47 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 142

FIGURE 48 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019) 143

FIGURE 49 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 143

FIGURE 50 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 144

FIGURE 51 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE (2020-2027) 144

FIGURE 52 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 161

FIGURE 53 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019) 162

FIGURE 54 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 162

FIGURE 55 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2020 & 2027) 163

FIGURE 56 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE (2020-2027) 163

FIGURE 57 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 222

FIGURE 58 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019) 223

FIGURE 59 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027) 223

FIGURE 60 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027) 224

FIGURE 61 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE(2020-2027) 224

FIGURE 62 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 288

FIGURE 63 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019) 289

FIGURE 64 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027) 289

FIGURE 65 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027) 290

FIGURE 66 SOUTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE (2020-2027) 290

FIGURE 67 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019) 307

FIGURE 68 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019) 308

FIGURE 69 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027) 308

FIGURE 70 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027) 309

FIGURE 71 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE (2020-2027) 309

FIGURE 72 GLOBAL OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 336

FIGURE 73 NORTH AMERICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 337

FIGURE 74 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 338

FIGURE 75 ASIA-PACIFIC OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%) 339

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Avestia Pharma

Novasep

AbbVie Inc.

KD Pharma Group

BASF SE

Corbion NV

DSM

AstraZeneca

GlaxoSmithKline plc.

Fresenius Kabi AG

Croda International Plc

AMARIN CORPORATION

ANI Pharmaceuticals, Inc.

Epax

Strides Pharma Science Limited

Pharma Marine AS

KinOmega Biopharm Inc.

Camber Pharmaceuticals, Inc.

Solutex